VALOPES Competitors

Capsule is rebuilding the $425 billion pharmacy industry from the inside out with an emotionally resonant brand and technology that enables customized outcomes for doctors, hospitals, insurers, and manufacturers. Our team makes the same promise to each other as the one we’ve made to our customers, doctors, and partners: everybody needs some looking after sometimes. We’ll never lose sight of the fact that behind all the craziness of the healthcare system, we’re just people looking after other people. Capsule has raised over $500MM from the best healthcare and technology investors in the world.

RxVantage transforms how medical practices access life science resources. By automating scheduling and streamlining communication, RxVantage gives practices a powerful connection to the innovative solutions that are revolutionizing patient care. Our apps intelligently connect healthcare providers with the precise life sciences experts that they need, when they need them. As a result, medical practices stay on the cutting edge of patient care without disrupting workflows. Trusted by more than 17,000 medical practices and all major life science companies, RxVantage powers more than 1M+ educational exchanges every year between healthcare providers, their staff, and life science experts. We are on the hunt for exceptional talent that is eager to help build a great company.

Careplus (M) Sdn Bhd was incorporated in Malaysia on 30 March 2010 as a private limited company under the name of Careplus Group Sdn. Bhd. Subsequently, on 5 April 2010, we converted our status from a private limited company to a public limited company to facilitate our listing on the ACE Market of Bursa Securities. We are principally an investment holding company whilst our subsidiaries are involved in the manufacturing, processing and trading of gloves. Careplus has also on 5 February 2020 entered into a joint venture arrangement with Ansell Services (Asia) Sdn. Bhd. (“Ansell”) for the disposal, via a conditional SPA entered into between Careplus and Ansell, of 50% equity interest in Careplus (M) Sdn. Bhd. (“CMSB”), consisting of 14,550,000 ordinary shares in CMSB for a disposal consideration of approximately RM26.97 million, to be satisfied entirely by cash (“Disposal”). Upon completion of the Disposal and in accordance with the terms of the Shareholders’ Agreement entered into between Careplus, Ansell and CMSB, CMSB ceased to be a wholly-owned subsidiary of Careplus and became a 50% of joint venture of Careplus.